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Improving Assessment of Aortic Stenosis
Philippe Pibarot, DVM, PHD, Jean G. Dumesnil, MD
Québec, Québec, Canada
“Degenerative” or calcific aortic stenosis is a complex, multifaceted, systemic disease that is not solely limited
to the aortic valve but also includes reduced arterial compliance as well as alterations of left ventricular geome-
try and function. This particular nature of the disease underscores the need for a more comprehensive evalua-
tion of disease severity going beyond the standard parameters routinely used to assess stenosis severity (i.e.,
peak jet velocity, pressure gradients, valve effective orifice area) or left ventricle function (i.e., left ventricular
ejection fraction). The present paper thus proposes to review newer approaches to improve the quantification of
disease severity taking into account the interrelation between the different valvular, arterial, and ventricular vari-
ables that may be responsible for the appearance of symptoms and/or poorer prognosis in patients with aortic
stenosis. (J Am Coll Cardiol 2012;60:169–80) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.11.078h
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fAortic stenosis (AS) is a complex “systemic” disease. There
are compelling epidemiological and histopathological data
suggesting that “degenerative” calcific AS is, in fact, an
active and multifaceted disease that involves atherosclerotic-
like and elastocalcinosis-like processes (1). Hence, it is not
surprising that many patients with this disease also have
manifestations of these pathologic processes in other target
organs. In particular, a large proportion of patients with AS
also present with concomitant systolic hypertension, which
is related to increased rigidity of the arterial wall (2).
Moreover, these patients may have alterations of left ven-
tricular (LV) function that might not only be due to AS but
also to concomitant hypertension or coronary artery disease
and in varying proportions depending on the severity of
each entity (2). In this context, it should be emphasized that
the pathophysiology of adverse outcomes in AS is essentially
due to an imbalance between the increase in LV hemody-
namic load due to the valvular obstruction and/or concom-
itant arterial hypertension, on the one hand, and the
capacity of the left ventricle to overcome this increase in
load both at rest and during exercise, on the other hand.
The present paper thus proposes to review newer ap-
proaches to improve the quantification of disease severity,
taking into account the interrelation between the different
valvular, arterial, and ventricular variables that may be
responsible for the appearance of symptoms or poorer
prognosis in patients with AS.
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accepted November 12, 2011.Assessing AS Severity: New Challenges
The American College of Cardiology (ACC)/American
Heart Association (AHA) and European Society of Cardi-
ology (ESC) guidelines generally recommend aortic valve
replacement (AVR) in patients with severe AS who have
symptoms, LV systolic dysfunction, and/or undergo cor-
onary artery bypass graft surgery or other heart surgery
(Fig. 1) (3,4). And the criteria proposed in these guidelines
to identify severity are a peak aortic jet velocity 4.0 m/s, a
mean gradient40 mm Hg and a valve effective orifice area
(EOA) 1.0 cm2. These parameters and criteria may,
owever, have important limitations if used in isolation
Table 1), and it has become evident that the evaluation of
S severity, particularly in patients with the “degenerative”
orm of the disease, is confronted with specific challenges, as
ollows.
ccounting for pressure recovery. The current guidelines
3,4) make no distinction between catheterization and
oppler echocardiographic measurements as if values for
radients and EOA measured by either technique were
nterchangeable (Fig. 1). Yet, Doppler estimates the maxi-
al pressure drop through the valve from the maximal
elocity recorded at that level whereas catheterization pro-
ides a measure of the net gradient between the left ventricle
nd the ascending aorta (Fig. 2). However, as blood flow
elocity decelerates between the valve and the ascending
orta, part of the kinetic energy is reconverted back to static
nergy due to a phenomenon called pressure recovery, and
ence the net gradient recorded at catheterization is always
ess than the maximum pressure gradient measured by
oppler (Fig. 2) (2,5–7). Likewise, EOA obtained at
atheterization with the use of the Gorlin formula is derived
rom recovered pressures, such that its value is higher than
he Doppler EOA derived by the continuity equation. The
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Improving Assessment of Aortic Stenosis July 17, 2012:169–80latter measures the actual area
occupied by flow at the valvular
level whereas the EOA calcu-
lated by the Gorlin formula is a
coefficient of the energy lost due
to the stenosis rather than a true
EOA. The extent of pressure re-
covery is determined by the ratio
between the valve EOA and the
cross-sectional area of the as-
cending aorta, a situation that
becomes particularly relevant in
patients with moderate to severe
AS (Doppler EOA between 0.8
cm2 and 1.2 cm2) and small aor-
tas (diameter at the sinotubular
junction 30 mm) where mea-
surement of EOA by Doppler echo-
cardiography may lead to over-
estimation of severity (2,5–7).
Fortunately, pressure recovery can be
accounted for by using the formula
proposed by Baumgartner et al. (5)
to estimate the net gradient from
Doppler measurements, as well as
he formula proposed by Garcia et al. (6) to calculate the energy
oss coefficient: ELCo (EOAAA / AAEOA), where AA
is the cross-sectional area of the aorta measured at 1 cm
downstream of the sinotubular junction (Table 1) (6). This
parameter is more or less equivalent to the EOA obtained
by catheterization with the use of the Gorlin formula (6–8),
and physiologically, it is more representative than the
Doppler EOA of the actual energy loss caused by the stenosis
and thus of the increased burden imposed on the ventricle. The
stroke work loss, which is the ratio of the mean transvalvular
gradient to the estimated LV systolic pressure, is another index
that indirectly accounts for the pressure recovery (Table 1).
And accordingly, this parameter has also been shown to be
superior to the gradient or the EOA for predicting clinical
outcomes (9).
Accounting for body size. Valve EOA and energy loss
coefficient do not take into account cardiac output
requirements in a given patient and, hence, for a similar
EOA and cardiac index, gradients and the burden im-
posed by the stenosis on the ventricle will be higher in
patients with a larger body size than in smaller patients.
It thus follows that AS severity may be significantly
overestimated in smaller patients and underestimated in
larger patients when using nonindexed EOA or energy
loss coefficient. Conversely, the utilization of parameters
indexed for body surface area may overestimate stenosis
severity in obese patients.
Accounting for inconsistencies in the guidelines criteria.
The guidelines (3,4) are inconsistent from 2 standpoints.
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
AS  aortic stenosis
AVR  aortic valve
replacement
BNP  brain natriuretic
peptide
CMR  cardiac magnetic
resonance
CT  computed
tomography
EOA  effective orifice
area
ESC  European Society of
Cardiology
LV  left ventricular
LVEF  left ventricular
ejection fraction
Zva  valvuloarterial
impedanceFirst, the criteria used to define severe AS are derived nfrom outcome studies based on catheterization data, yet
the guidelines make no distinction between echo and
catheterization data although, due to pressure recovery
(as discussed earlier), gradients will always tend to be
higher and EOA lower by echocardiography than by
catheterization. Second, the severity criteria are also
inherently inconsistent with each other (10,11). Indeed,
in a patient with normal transvalvular flow rate, the mean
gradient that theoretically corresponds to an EOA value
of 1.0 cm2 is closer to 30 to 35 mm Hg rather than to the
0 mm Hg cutoff value as proposed in the guidelines
3,4). In light of these findings, some investigators have
uggested to lower the cutoff value of EOA for severe AS
rom 1.0 cm2 to 0.8 cm2 (11). However, several studies report
hat a valve EOA 1.0 cm2 does indeed predict excess
ortality and morbidity irrespective of the level of gradient and
he presence of symptoms (12,13). Hence, further studies are
eeded to determine the outcome of the particular subset of
atients with an EOA between 0.8 cm2 and 1.0 cm2, especially
when treated conservatively.
Accounting for vascular load. Elderly patients with cal-
ific AS may also have arterial atherosclerosis as well as
edial elastocalcinosis. Young subjects with a bicuspid
ortic valve also commonly have reduced aortic elasticity
s a result of structural abnormalities of the aortic wall
nd/or aortic dilation (14). Hence, it is not surprising that
atients with calcific AS often have reduced compliance in
he large arterial circulation and thereby ensuing systolic
ypertension (2,14). Briand et al. (2) reported that total
ystemic arterial compliance estimated by dividing the
troke volume index as measured by echocardiography by
ulse pressure (systolic minus diastolic blood pressures) is
everely reduced (0.6 ml·m2 · mm Hg1) in approxi-
ately 40% of patients with AS (Table 1). Furthermore,
educed arterial compliance contributes to increase the LV
fterload and thus the occurrence of myocardial dysfunction
nd adverse events. Besides the pulsatile component of the
rterial load reflected by the systemic arterial compliance,
here is also the steady component that is estimated by
alculating the systemic vascular resistance (SVR) as fol-
ows: SVR  (80  mean arterial pressure)/cardiac output,
here cardiac output is measured in the LV outflow tract by
oppler echocardiography and mean arterial pressure is
efined as diastolic pressure plus one-third of pulse pressure
Table 1). Finally, it should be emphasized that a normal
lood pressure does not exclude an increase in vascular load
ince these pressures may be pseudo-normalized in up to
0% of patients with decreased systemic arterial compliance
ue to LV dysfunction and a concomitant decrease in
ardiac output (2,12).
nteraction between hypertension and aortic stenosis severity
riteria. In light of the above, concomitant arterial hyper-
ension is found to be present in a large proportion (35%
o 51%) of patients with AS (2,12,15–17). Hence, there
hould be awareness that the parameters of AS severity may be
oticeably altered by the presence of hypertension, and that
171JACC Vol. 60, No. 3, 2012 Pibarot and Dumesnil
July 17, 2012:169–80 Improving Assessment of Aortic StenosisFigure 1 Algorithm for Management of Patients With AS
Algorithms for the management of (A) severe aortic stenosis (AS) and (B) moderate AS. The text in black refers to the recommendations proposed in the American Col-
lege of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) guidelines whereas the text in red and between [ ]? represents the
new emerging parameters that may eventually contribute to improving the assessment and management of AS. However, these new parameters will need to be further
validated in future studies. AVR  aortic valve replacement; BNP  brain natriuretic peptide; BP  blood pressure; CABG  coronary artery bypass graft surgery; CAD 
coronary artery disease; CT  computed tomography; echo  echocardiography; EOA  effective valve orifice area; FU  follow-up; LV  left ventricular; VPeak  peak
aortic jet velocity.
172 Pibarot and Dumesnil JACC Vol. 60, No. 3, 2012
Improving Assessment of Aortic Stenosis July 17, 2012:169–80there is no readily available mean of accounting for this
phenomenon. Indeed, reduced arterial compliance tends to
abolish the peak-to-peak gradient as recorded during catheter-
ization (18) as well as modify the other parameters of AS
severity (2,18,19). These latter modifications occurring with
Parameters for the Assessment of Aortic StenosisTable 1 Parameters for the Assessment of Aortic Stenosis
Parameter Criteria for Severe
Quantification of valvular obstruction
Peak aortic jet velocity (VPeak)*† 4 m/s Easy to
Low int
High sp
Mean gradient*† 40 mm Hg Same a
Valve effective orifice area*†
EOA  SVLVOT/VTIAo
Indexed EOA*
EOAI  EOA/BSA
1.0 cm2
0.6 cm2/m2
Less flo
peak
Reflect
Energy loss index
ELI  [EOA AA/AAEOA]/BSA
0.5–0.6 cm2/m2 Less flo
peak
Takes i
 eq
Reflect
Should
aort
Stroke work loss
SWL  100 (PMean/SBPPMean)
25% Less flo
velo
Takes i
Aortic valve calcification score† Echo 4/4† Can be
mea
CT 1,650 AU Correla
pred
Indepen
Useful
of st
inco
Quantification of vascular load
Systemic BP* 140/90 mm Hg Easy to
SBP/DBP
Systemic arterial compliance* 0.6 ml·mm Hg1·m2 Can be
SAC  SVI/SBPDBP* Most fr
in AS
Can un
pseu
Systemic vascular resistance* 2,000 dyne·s·cm5 Can be
SVR  80MBP/CO Can un
pseuchanges in blood pressure are essentially related to the con-comitant changes in mean transvalvular flow rate, and stenosis
severity may be over- or under-estimated depending on the
direction of these flow changes (18,19).
Accounting for low flow states. The chronic exposure to a
high level of afterload may eventually exceed the limit of LV
Utility and Advantages Limitations
ure Highly flow dependent
rver/intraobserver variability
y
Over-estimates LV energy loss in patients
with small aortas
May under- or over-estimate stenosis
severity in presence of hypertension
Under-estimates stenosis severity in low
flow states
aortic jet velocity Same as peak aortic jet velocity
endent than gradient or
ity
sic severity of valvular obstruction
Susceptible to measurements errors
Over-estimates LV energy loss in patients
with small aortas
May under- or over-estimate stenosis
severity in presence of hypertension
May over-estimate stenosis severity in
low flow states
EOA may over-estimate severity in
patients with small body size.
Indexed EOA may over-estimate severity
in obese patients
endent than gradient or
ity
Susceptible to measurements errors
May under- or over-estimate stenosis
severity in presence of hypertension
May over-estimate stenosis severity in
low flow states
count pressure recovery and is
nt to EOA measured by catheter
LV energy loss caused by stenosis
asured in patients with small
endent than gradient or peak
count pressure recovery
May under-estimate stenosis severity and
LV energy loss in presence of
hypertension
ted by echo and quantitatively
by multislice CT
Echo, semiquantitative assessment
CT, exposure to radiation
ll with stenosis severity and
pid stenosis progression
f hemodynamic conditions
flow states when echo assessment
hemodynamic severity is
e
ure Highly flow dependent
Often pseudonormalized in AS patients
Underestimates severity of hypertension
in low flow states
red by Doppler echocardiography Susceptible to measurements errors
cause of increased arterial load
nts
ypertension in patients with
malized blood pressure
red by Doppler echocardiography Susceptible to measurements errors
ypertension in patients with
malized blood pressure
Continued on next pagemeas
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July 17, 2012:169–80 Improving Assessment of Aortic Stenosisment of myocardial function and a decrease in cardiac
output resulting in a decrease in transvalvular gradients and
a pseudonormalization of peripheral blood pressure. This
situation is highly insidious because both AS and hyperten-
sion may appear less severe on the basis of the gradient and
blood pressure, whereas, in fact, these patients are at a more
advanced stage of their disease. Low-flow, low-gradient AS
may occur with reduced or preserved LV ejection fraction,
and both situations are among the most challenging en-
countered in patients with AS. (This topic will be addressed
in detail in a forthcoming state-of-the-art paper in the
Journal.)
Assessment of AS Severity: New Solutions
Many patients with AS can still be managed adequately
with the use of simple parameters of disease severity such as
peak jet velocity, mean gradient, EOA, valve morphology, and
LV ejection fraction (LVEF) (Figs. 1 and 2, Table 1). However,
in light of the earlier noted considerations, it becomes
evident that the mode of presentation of many patients with
calcific AS is more complex than previously believed and
thus warrants more comprehensive evaluations, which can
ContinuedTable 1 Continued
Parameter Criteria for Severe
Quantification of global LV
hemodynamic load
Valvuloarterial impedance (Zva)* 4.5 mm Hg·ml
1·m2 Can be
Zva  SBPPMean/SVI Reflect
on L
Potenti
sym
Quantification of LV systolic dysfunction
LVEF*† 50% Widely
outc
Global longitudinal strain* 15% Less in
Superio
myo
Myocardial fibrosis Can be
Predict
Plasma natriuretic peptides*
BNP or NT-ProBNP
Easy an
Reflect
myocar
Correla
dysf
Predict
*Indicates the parameters we think should be part of the routine assessment of patients with aort
College of Cardiology/American Heart Association and European Society of Cardiology guidelines
AA cross-sectional area of the ascending aortameasured just downstream of the sinotubular ju
ardiac magnetic resonance; CO  cardiac output; DBP  diastolic blood pressure; Echo  echoc
T-ProBNP  N-terminal pro–B-type natriuretic peptide; SBP  systolic blood pressure; SVI  stroinclude the following: iAssessment of valvular load. The energy loss index is the
energy loss coefficient divided by body surface area; it takes
into account the effects of both pressure recovery and body
size. In a substudy of the SEAS (Simvastatin Ezetimibe in
Aortic Stenosis) trial (20), 47.5% of patients classified as
having severe AS by indexed EOA were reclassified to
nonsevere AS when using energy loss index. Moreover, this
parameter allows easier comparison between echocardio-
graphic and catheterization data (21). The threshold value
for severe stenosis is 0.5 to 0.6 cm2/m2 (Table 1) (6,7,20).
ssessment of vascular load. The increase in global LV
emodynamic load due to decreased systemic arterial com-
liance and/or increased vascular resistance can be impor-
ant in many patients. Accordingly, Antonini-Canterin et
l. (15) have observed that symptoms of AS develop at a
ower degree of stenosis severity in hypertensive patients,
ost likely because of the additional hemodynamic load due
o hypertension. Hence, blood pressure should be routinely
ecorded in patients evaluated for AS, and systemic arterial
ompliance and vascular resistance should also be calculated
s blood pressure can be pseudonormalized in as many as
0% of patients (Table 1). Given that hypertension may
Utility and Advantages Limitations
red by Doppler echocardiography Susceptible to measurements errors
l (valvulararterial) load imposed Does not permit to discriminate the
valvular versus the arterial contribution to
the global LV loadperior to predict occurrence of
and events
nd validated with regard to
ata
Susceptible to measurements errors
Also influenced by LV geometry
Under-estimates the degree of myocardial
systolic dysfunction in presence of
LV concentric remodeling
d by LV geometry Cutoff values need to be further validated
EF to assess intrinsic
l function
red by CMR High cost and low availability of CMR
outcomes after AVR
pensive to measure
l burden of disease on
High variability in the threshold values
reported in the literature to predict
poor outcomes
ll with myocardial systolic
and symptoms
outcomes before and after AVR
Increase in BNP during serial follow-up
may be superior to isolated measure
Does not permit discriminating impact of
valvular stenosis versus hypertension
versus other cardiovascular disease
NT-ProBNP may be more sensitive to
detect early LV systolic dysfunction but
more age dependent
sis (AS). †Indicates the parameters that are included in the algorithms presented in the American
management of AS.
AVR aortic valve replacement; BNP brain natriuretic peptide; BSA body surface area; CMR
phy; LV  left ventricular; LVEF  left ventricular ejection fraction; MBP  mean blood pressure;
me index.measu
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V
ally su
ptoms
used a
ome d
fluence
r to LV
cardia
measu
s poor
d inex
s tota
dium
tes we
unction
s poor
ic steno
for the
nction;nterfere with the assessment of AS severity and that
p
d
(
n
m
v
A
r
a
p
w
t
h
i
t
k
174 Pibarot and Dumesnil JACC Vol. 60, No. 3, 2012
Improving Assessment of Aortic Stenosis July 17, 2012:169–80there is no easy means of correcting for this distortion,
the following should also be considered: 1) evaluation of
AS severity by echocardiogram or catheterization should
ideally be performed when blood pressure control is
optimal; 2) serial evaluations should take into account if
the patient’s blood pressure and flow levels are within the
same range as the previous evaluation; and 3) in case of
discrepancies between Doppler echocardiographic and
catheterization data, potential differences in blood pres-
sure and transvalvular flow rates during each examination
should be considered.
Assessment of global LV hemodynamic load. To assess
the global (valvular plus arterial) LV hemodynamic load in
AS patients, one can calculate the valvuloarterial impedance
(Zva) (Fig. 2) by dividing the estimated LV systolic pressure
(systolic blood pressure plus mean transvalvular gradient) by
the stroke volume indexed for body surface area (Table 1)
(2). This parameter provides an estimate of the cost in mm
Hg for each systemic milliliter of blood indexed for body
size pumped by the left ventricle. Values of Zva 3.5 and
4.5 mm Hg·ml1· m2 indicate moderately and severely
increased global LV hemodynamic load respectively (17).
The Zva has been shown to be superior to the standard
arameters of AS severity (i.e., gradients and EOA) in pre-
icting LV dysfunction and patient clinical outcomes
Figure 2 Blood Flow and Pressure Across LVOT, Aortic Valve, a
When the blood flow contracts to pass through a stenotic orifice (i.e., the anatomi
is converted into kinetic energy, namely, velocity, thus resulting in a pressure drop
area [EOA]), a large part of the kinetic energy is irreversibly dissipated as heat be
verted back to potential energy is called the “pressure recovery” (PR). The global h
vular load and the arterial load. This global load can be estimated by calculating t
the impedance can be calculated with the standard Doppler mean gradient in plac
sinotubular junction; Pmax  maximum transvalvular pressure gradient recorded
transvalvular pressure gradient recorded after pressure recovery (i.e., mean gradie
sure in the LVOT; SBP  systolic blood pressure; SVi  stroke volume index; Vpea2,16,17,22,23). This parameter is useful with regard to prog-osis but it remains important, from the standpoint of treat-
ent, to delineate the relative contributions of the valvular and
ascular components to the increased load.
ssessment of LV geometry. The pattern of the LV
esponse to pressure overload in AS is highly heterogeneous
nd includes concentric remodeling, concentric hypertro-
hy, and eccentric hypertrophy (24–26). Hence, relative
all thickness should be systematically measured in addition
o LV mass because a large proportion of patients with AS
ave abnormal LV geometry (relative wall thickness 0.42;
.e., concentric remodeling) despite absence of LV hyper-
rophy defined as indexed LV mass 95 g/m2 in women
and 115 g/m2 in men (16,25,26). More severe LV
concentric remodeling or hypertrophy has been linked to
worse myocardial function (16), increased risk of cardiovas-
cular events (27), and increased operative and late mortality
after aortic valve replacement (28). The pattern and mag-
nitude of the LV adaptive response to AS is influenced by
several factors including stenosis severity, age, sex, obesity,
metabolic syndrome, and diabetes mellitus (24–26).
Assessment of intrinsic LV function, going beyond LVEF.
Left ventricular systolic dysfunction on the basis of LVEF is
a class I indication for AVR in patients with severe AS
irrespective of symptoms, and LVEF is the only parameter
scending Aorta During Systole
e area [AOA]), a portion of the potential energy of the blood, namely, pressure,
cceleration of flow. Downstream of the vena contracta (i.e., the effective orifice
of flow turbulences. The remaining portion of the kinetic energy that is recon-
ynamic load imposed on the left ventricle results from the summation of the val-
uloarterial impedance. In patients with medium or large size ascending aorta,
e net mean gradient. AA  cross-sectional area of the aorta at the level of the
level of vena contracta (i.e., mean gradient measured by Doppler); Pnet  net
asured by catheterization); LVOT  left ventricular outflow tract; PLVOT  pres-
ak aortic jet velocity; Zva  valvuloarterial impedance.nd A
c orific
and a
cause
emod
he valv
e of th
at the
nt me
 peof LV function included in the guidelines (3,4). Yet, several
175JACC Vol. 60, No. 3, 2012 Pibarot and Dumesnil
July 17, 2012:169–80 Improving Assessment of Aortic Stenosisstudies report that as many as one-third of asymptomatic
patients with preserved LVEF have a significant impair-
ment of intrinsic myocardial systolic function (16,22,29,30)
and that the parameters of LV longitudinal kinetics are
superior to other indices of LV systolic function to detect
Figure 3 Superiority of LV Longitudinal Shortening Over LVEF to
The panels show the left ventricles (LV) of (A) a normal healthy subject, (B) a pat
advanced AS and myocardial dysfunction. The LV ejection fraction (LVEF) markedly
centric hypertrophy such as is often the case in AS patients (C). The increase in w
tion of wall thickening to endocardial inward displacement (B and C). As a conseq
normal in presence of concentric hypertrophy, despite a significant impairment of
more sensitive than LVEF to identify intrinsic myocardial dysfunction.myocardial dysfunction and damage (Fig. 3) (23,29–33) as
well as to predict symptoms, exercise tolerance, and out-
comes (22,31,34–36). From a pathophysiological stand-
point, these data are consistent with the concept that: 1) the
increase in wall stress and intramyocardial pressure as well as
tify Myocardial Systolic Dysfunction in AS
th aortic stenosis (AS) and normal myocardial function, and (C) a patient with
estimates the extent of myocardial systolic impairment in presence of LV con-
ckness associated with LV concentric hypertrophy results in a greater contribu-
, LVEF as well as any parameter based on endocardial displacement remains
ic myocardial shortening and function (C). The longitudinal strain (LS) is thusIden
ient wi
under
all thi
uence
intrins
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Improving Assessment of Aortic Stenosis July 17, 2012:169–80the reduction in myocardial blood flow in AS occur mainly
in the subendocardium; and 2) the subendocardial myocar-
dial fibers are oriented longitudinally. Hence, as hypothe-
sized by Dumesnil et al. (29) 30 years ago, the selective
impairment in longitudinal LV shortening is likely the
consequence of increased subendocardial wall stress and
resulting subendocardial ischemia and/or fibrosis. Global
longitudinal myocardial strain measured by speckle tracking
can now be measured routinely and reproducibly and has
emerged as the most promising alternative to detect and
quantify intrinsic myocardial systolic dysfunction (30–32); pend-
Figure 4 Assessment of Myocardial Fibrosis by CMR and Echo
(A) The distribution of late gadolinium enhancement (LE) (top), expressed as perc
defined according to the severity of fibrosis in endomyocardial biopsies. The conco
cardial biopsy for the quantification of myocardial fibrosis in patients with severe a
longitudinal shortening assessed with the use of the mitral ring displacement prov
sion of the American College of Cardiology (23).ing further validation, a threshold value of 15% has been
proposed for this purpose (22,30).
Identifying myocardial damage by measuring fibrosis and
BNP levels. Recent studies (33,37) have reported that about
one-third of patients undergoing AVR for severe AS have
severe myocardial fibrosis documented by cardiac magnetic
resonance (CMR) and intraoperative myocardial biopsies
(Fig. 4). Moreover, myocardial fibrosis is often not, or
only partially, reversible and is associated with increased
risk of cardiovascular events and mortality during follow-
up as well as persistence of LV dysfunction and symptoms
ography in AS
(range 0% to 100%) at baseline and 9 months post-AVR within the 3 groups, is
e between (middle) cardiac magnetic resonance (CMR) and (bottom) endomyo-
tenosis (AS) undergoing aortic valve replacement (AVR). (B) The left ventricular
good surrogate marker of the extent of myocardial fibrosis. Adapted with permis-cardi
entage
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July 17, 2012:169–80 Improving Assessment of Aortic Stenosis(23,33,37,38). The nonreversibility of myocardial fibrosis
and associated dysfunction after AVR most likely depends
on the type (replacement vs. interstitial) and extent (severe
vs. mild) of fibrosis. Hence, the quantification of myocardial
fibrosis by CMR could potentially be useful to improve risk
stratification and follow-up as well as to recommend AVR
before extensive fibrosis and ensuing irreversible myocardial
dysfunction have developed. The implementation of such a
measure is, however, unrealistic due to high cost and low
availability. Conversely, it has been shown that the param-
eters of LV longitudinal function correlate well with the
degree of myocardial fibrosis (Fig. 4) (23,29,33). Hence, an
alternate approach could be to routinely measure global LV
longitudinal strain during follow-up and to perform CMR
in selected cases.
Recent studies also show that brain natriuretic peptide
(BNP) levels correlate better with myocardial abnormalities
(i.e., LVEF, LV longitudinal shortening, degree of myocar-
dial fibrosis) and clinical outcomes than the usual parame-
ters of AS severity (23,31,33,36,39–42). These findings
further corroborate the concept that myocardial damage and
clinical outcomes are primarily determined by the total
burden of disease on the ventricle rather than by AS severity
alone (Table 1). First, levels of BNP may also have an added
advantage over the indices of global load such as Zva in that
hey also likely reflect the impact of other associated
onditions (e.g., coronary artery disease, cardiomyopathy,
nd so forth) on the myocardium. However, BNP levels are
ot specific to AS severity alone but rather reflect the total
urden of disease on the left ventricle. They should thus be
nterpreted in light of the parameters more specifically
eflecting AS severity as well as arterial and global loads
Table 1). Second, the threshold values for adverse events
ppear to vary considerably from one study to the other.
hird, BNP response is also influenced by age and sex.
ence, unless the value are unequivocally elevated (e.g.,
NP 500 pg/ml) (40,41), an individual result should not
e interpreted in isolation but rather in light of other clinical
ariables as well as variations with time, which may be
uperior to an individual measurement to predict develop-
ent of symptoms (43). For NT-proBNP, which is influ-
nced by age, reference values in relation to the different age
trata also need to be established. Nonetheless, BNP re-
ains a robust predictor of outcomes in AS, and we believe
t should be routinely measured and become an integral part
f the clinical decision making process. Moreover, it may
ave added value from the standpoint of cost-benefit since
he continued observation of low and stable levels in an
symptomatic patient might preclude the unnecessary use of
ore expensive investigations.
xercise testing to unmask symptoms. The onset of
ymptoms is one of the cornerstones in the decision-making
lgorithm presented in the ACC/AHA and ESC guidelines
or the indications of AVR (Fig. 1) (3,4). However, the
oncept proposed 40 years ago, of patients with AS remain-
ng asymptomatic for a long time and then developingxplicit symptoms portending poor outcomes (44), is no
onger congruent with the new face of the disease that we
ncounter nowadays. Indeed, elderly patients have more
omorbidities and are less physically active, which renders
he assessment of symptoms much more complex and
nreliable. Patients may also reduce their level of physical
ctivity to avoid or minimize symptoms, and the overall
resentation often predisposes to under-reporting and/or
nder-estimation of symptoms. Conversely, because of as-
ociated comorbidities, it may be difficult to determine if the
ymptoms are really due to the valvular stenosis per se.
omen are referred to AVR at a more advanced stage of
he disease compared to men, which may, at least in part,
ontribute to the increased operative risk frequently associ-
ted with female sex (45).
Several studies have now demonstrated that exercise
esting can be done safely in patients without apparent
ymptoms (46) and that the results can be used to identify
atients at high risk of adverse events over the next 1 to 2
ears (47–50). Both the ACC/AHA and ESC guidelines
3,4) now support the role of exercise testing in asymptom-
tic AS patients, with recommendations that AVR be
onsidered in those with exercise-induced symptoms or
bnormal blood pressure responses (Fig. 1). The strength of
his recommendation, however, differs between the 2 guide-
ines, with a Class IIb recommendation from the ACC/
HA compared to Class I (symptoms) and Class IIa
abnormal blood pressure) recommendations from the ESC.
or older or less active patients, the negative predictive value
f exercise testing remains high so that the absence of
xercise-limiting symptoms or fall in blood pressure is
eassuring; however, the positive predictive value is lower in
hese patients (49) so that the results of exercise testing
hould be interpreted in light of other risk markers (i.e., Zva,
BNP, and so forth) and comorbidities (Fig. 1). Finally, 2
studies have shown that among patients with moderate or
severe AS, those who display an increase in mean gradient
of 18 to 20 mm Hg during exercise testing have a higher
risk of progression to symptoms and adverse events (50,51).
These observations might become an argument for combin-
ing exercise testing with stress echocardiography when
evaluating these patients.
Other factors related to more rapid disease progression.
Several other factors have been identified as predisposing to
more rapid disease progression (Fig. 1). 1) Patients with a
more severe stenosis defined as a valve EOA 0.6 cm2 or
peak aortic jet velocity 5.5 m/s have a more rapid
progression to symptoms and LV systolic dysfunction (52–54).
2) The degree of aortic valve calcification is also a powerful
predictor of more rapid stenosis progression (53). Semi-
quantitative scoring of valve calcification can be done by
echocardiography but multislice computed tomography
(CT) allows more accurate and quantitative assessments
(55). The concern of radiation exposure, however, limits the
use of this procedure for routine follow-up. 3) Previous
studies report an association between several traditional
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Improving Assessment of Aortic Stenosis July 17, 2012:169–80cardiovascular risk factors (i.e., hypercholesterolemia, hy-
pertension, obesity, smoking) and faster stenosis progression
but there is until now no evidence that this situation can be
altered by medications targeting these risk factors (e.g.,
statins, inhibitors of the renin-angiotensin system) (1).
Moreover, there is mounting evidence that the metabolic
syndrome and type 2 diabetes are also associated with faster
stenosis progression and faster deterioration of LV function
(25,56), but it remains to be determined if the course of the
disease can be altered by changes in lifestyle and/or thera-
pies targeting the associated metabolic abnormalities.
Important caveats. The utility, advantages, and limitations
of the various parameters used to evaluate stenosis severity
are summarized in Table 1 and have been extensively
iscussed in the American Society of Echocardiography/
uropean Association of Echocardiography guidelines (21).
iven that all parameters of stenosis severity have limita-
ions and may be subject to measurement errors, a compre-
ensive, multiparametric approach is thus recommended.
ence, AS severity is best characterized by flow-independent
arameters such as EOA, indexed EOA, and energy loss
ndex, but their estimation, however, requires the inclusion
f several parameters and they are therefore more prone to
easurement errors.
The degree of valve calcification measured by multislice
T can also be used to corroborate stenosis severity, a
alcium score 1,650 AU being indicative of severe AS
ith a sensitivity and specificity 80% (55). The main
dvantage of this parameter is that it is not influenced by
emodynamic conditions, and it may thus be particularly
seful in the presence of low LV outflow states. The
isadvantage of CT calcium scoring is exposure to ionizing
adiation (1 to 3 mSv per examination), which limits serial
hort-time interval follow-up. This radiation risk is, how-
ver, a less important issue in the elderly patients who
epresent an important proportion of the AS population.
uture studies are needed to further validate and standardize
he utilization of such multiparametric/multimodality ap-
roach as well as to determine the potential clinical benefits
nd cost effectiveness of multidisciplinary specialized heart
alve clinics.
esolving Difficult Clinical Situations in AS
anagement of patients with asymptomatic severe AS.
he management of patients with asymptomatic severe AS
emains a source of debate (3,4), and recent studies have
uggested that those treated surgically may have better
urvival than those treated medically (57). This difference
ay be related to under-estimation of symptoms and/or
tenosis severity, especially in the elderly sedentary patients
12). Moreover, a “wait for symptoms” strategy may result in
ome patients being operated too late, namely, at a stage of
he disease when myocardial impairment has become, at
east in part, irreversible (Fig. 4).As emphasized in the guidelines (3,4), an important
bjective in asymptomatic patients with severe AS and
ormal LVEF is to ensure that the patient is truly asymp-
omatic to the extent of performing an exercise test if the
ymptomatic status is equivocal. Otherwise, earlier referral
or AVR despite the absence of symptoms can also be
onsidered (Class IIa or IIb indication in the guidelines)
hen the following markers of rapid disease progression are
resent (Fig. 1A): 1) severe aortic valve calcification (53,55);
) rapid hemodynamic progression of the stenosis at serial
chocardiographic examinations (52,53); and/or 3) very
evere AS (54).
In addition to the standard parameters (i.e., peak jet
elocity, gradient, EOA, valve calcification, and LVEF)
roposed in the guidelines to assess disease severity, several
ther emerging parameters may also be used to further
nhance risk stratification and clinical decision making in
hese patients: 1) energy loss index to more precisely assess
tenosis severity in patients with EOA between 0.8 and 1.0
m2 and small aorta diameter (30 mm); 2) Zva to deter-
ine the global (valvular plus arterial) LV hemodynamic
oad; 3) plasma BNP to assess the global impact of the
iseases on the myocardium; and 4) global longitudinal
train to confirm that myocardial systolic function is intrin-
ically normal. If 1 or more of these parameters is clearly
bnormal (Table 1), it would appear preferable to follow the
atients more closely with a clinical, BNP level and/or
chocardiographic evaluation every 3 to 6 months. If,
owever, those parameters are only mildly or moderately
bnormal, the same follow-up could be extended to 6 to 12
onths. These emerging parameters as well as proposed
omposite risk scores incorporating several parameters (42)
ill have to be further validated in large prospective studies
efore being implemented in routine practice.
anagement of patients with symptomatic moderate AS.
n patients with moderate AS who nonetheless have symp-
oms, the objectives are first to confirm that the stenosis is
eally moderate rather than severe, and then to determine
he probable etiology of the symptoms (Fig. 1B). In this
ontext, it is important to reiterate that adverse outcomes in
S are in fine determined by the imbalance between global
V load and LV myocardial reserve. Hence, a patient with
oderate AS and concomitant arterial hypertension may
ave a global hemodynamic load that is equivalent or
uperior to that of a patient with severe AS and no
ypertension, and thus be symptomatic on that basis (15).
he calculation of Zva may thus be useful in these cases to
econcile the apparent discrepancy between the moderate
tenosis and the severity of the symptoms (17). If Zva is
high, an optimal and prudent treatment of hypertension
would appear reasonable. Future studies are necessary to
determine if AVR should nonetheless be contemplated in
patients with optimal treatment of hypertension and persis-
tence of symptoms. If Zva is low, associated conditions such
as coronary artery disease, cardiomyopathy, pulmonary dis-
ease, and so forth, should be considered (Fig. 1B).
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July 17, 2012:169–80 Improving Assessment of Aortic StenosisFinally, AS severity may progress rapidly in a substan-
tial proportion of patients with moderate AS even if
asymptomatic. Hence, closer follow-up (6 to 12 months)
would appear judicious with such patients if there is
presence of severe valve calcification at echocardiography
or CT, large increase in gradient on exercise stress
echocardiogram, or progressive increase in BNP from one
examination to the other (Fig. 1B).
Conclusions
“Degenerative” or calcific AS is a complex, multifaceted,
and systemic disease that is not solely limited to the aortic
valve but also includes reduced arterial compliance as well as
alteration of LV geometry and function. This changing face
of the disease underlines the need for a more comprehensive
assessment of AS severity going beyond the simple mea-
surement of the standard parameters of stenosis severity
(i.e., peak jet velocity, pressure gradients, EOA) or LV
function (i.e., LVEF) to include the following parameters:
1) the energy loss index for the assessment of valvular load;
2) the systemic arterial compliance and valvular resistance
for the assessment of arterial load; and 3) the valvuloarterial
impedance and BNP to quantify the global LV hemody-
namic load and its repercussion on the myocardium, and
4) the global longitudinal strain to assess the presence and
severity of intrinsic myocardial dysfunction. Moreover, ex-
ercise stress testing and exercise stress echocardiography
provide important tools to unmask symptoms, lack of valve
opening reserve, and/or latent myocardial systolic dysfunc-
tion unrevealed by assessment in the resting state. Hence, a
comprehensive approach integrating these novel parameters
is often essential to appropriately assess the type of patient
presenting nowadays with this type of pathology. Moreover,
other imaging modalities such as CT and CMR may also be
helpful to complement or confirm the information obtained
by clinical evaluation, Doppler echocardiography, or blood
biomarker measurements.
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